During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Rajshekhar Chakraborty, MD, discusses the safety and tolerability of linvoseltamab with carfilzomib when used for the treatment of patients with relapsed/refractory multiple myeloma.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in ...

While androgen receptor (AR) inhibitors have long been a cornerstone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), the ARANOTE trial (NCT04736199) sets darolutamide (Nubeqa ...

Discover the latest breakthroughs in oncology, including pivotal FDA decisions, promising therapies, and new treatment ...

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.

Alicia Morgans, MD, MPH, discusses how the ARANOTE trial not only demonstrated clinical efficacy for the combination of ADT and darolutamide, but also highlighted key quality-of-life benefits that ...

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for ...

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...